Related Experiment Video
Updated: Dec 10, 2025

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
Published on: December 23, 2022
Atrial Cardiopathy and Likely Pathogenic Patent Foramen Ovale in Embolic Stroke of Undetermined Source
Ioannis A Leventis1, Dimitrios Sagris1, Davide Strambo2
1Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.
Insights
In patients with embolic stroke of undetermined source (ESUS), atrial cardiopathy and likely pathogenic patent foramen ovale (PFO) are inversely related. This suggests these conditions may not frequently coexist as causes of stroke.
Area of Science:
- Cardiology
- Neurology
- Stroke Research
Background:
- Atrial cardiopathy and patent foramen ovale (PFO) are potential causes of embolic stroke of undetermined source (ESUS).
- The co-occurrence and relationship between these two embolic sources in ESUS patients are not well understood.
Purpose of the Study:
- To investigate the relationship between atrial cardiopathy and likely pathogenic PFO in patients diagnosed with ESUS.
Main Methods:
- Atrial cardiopathy was defined by electrocardiogram findings (left atrial enlargement, PR prolongation, supraventricular extrasystoles).
- PFO presence was assessed using echocardiography; likely pathogenic PFO was determined by a Risk of Paradoxical Embolism score of 7-10.
- The study analyzed 367 ESUS patients with data on both conditions.
Main Results:
- Likely pathogenic PFO was found in 16.9% and atrial cardiopathy in 33.2% of ESUS patients.
- Only 1.1% of patients had both conditions.
- Atrial cardiopathy was less prevalent in patients with likely pathogenic PFO (6.5%) compared to those without (40.6%).
- Likely pathogenic PFO was less prevalent in patients with atrial cardiopathy (3.3%) compared to those without (23.7%).
Conclusions:
- The presence of atrial cardiopathy is inversely associated with the presence of likely pathogenic PFO in ESUS patients.
- These findings suggest that atrial cardiopathy and pathogenic PFO may be alternative rather than concurrent embolic mechanisms in ESUS.
Background:
Atrial cardiopathy and likely pathogenic patent foramen ovale (PFO) are two potential embolic sources in patients with embolic stroke of undetermined source (ESUS). The relationship between these two mechanisms among ESUS patients remains unclear.
Methods:
Atrial cardiopathy was defined as increased left atrial diameter index (> 23 mm/m2) or left atrial volume index (> 34 mL/m2), or PR prolongation (≥ 200 ms), or presence of supraventricular extrasystoles in the electrocardiograms performed during hospitalization for the index stoke. The presence of PFO was assessed by transthoracic echocardiography with microbubble test or by transesophageal echocardiography. The presence of PFO was considered as likely pathogenic if the Risk of Paradoxical Embolism score was 7 to 10.
Results:
Among 367 ESUS patients with available information about the presence of PFO and the presence of atrial cardiopathy (median age: 61 years, 40.6% women), likely pathogenic PFO was diagnosed in 62 (16.9%) and atrial cardiopathy in 122 (33.2%). Only 4 patients (1.1%) had both likely pathogenic PFO and atrial cardiopathy. The prevalence of atrial cardiopathy was lower in patients with likely pathogenic PFO (6.5%) compared with patients with likely incidental PFO (31.2%) or without PFO (40.6%) (Pearson's chi-square test: 26.08, p < 0.001; adjusted odds ratio [OR]: 0.28, 95% confidence interval [CI]: 0.09-0.86). The prevalence of likely pathogenic PFO was lower in patients with atrial cardiopathy compared with patients without atrial cardiopathy (3.3% vs. 23.7%, respectively [Pearson's chi-square test: 24.13, p < 0.001; adjusted OR: 0.2, 95% CI: 0.02-0.6]).
Conclusion:
The presence of atrial cardiopathy is inversely related to the presence of likely pathogenic PFO in patients with ESUS.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Pulmonary Embolism I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Coronary Artery Disease II: Pathophysiology
Cardiomyopathy I: Introduction and Classification
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

